SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2016 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company’s clinical programs at the 28th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 30th at 8:30 a.m. Eastern Time.
Links to a live audio webcast and replay of these presentations may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, (formerly BCX4430), a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and is currently marketed in the U.S., Japan, Taiwan and Korea. Post-marketing commitment development activities are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910
